Fig. 4: Dual blockade of CD73 and CD155 enhances anti-tumor immune responses in immunocompetent GBM mouse model.
From: synNotch-programmed iPSC-derived NK cells usurp TIGIT and CD73 activities for glioblastoma therapy
A Study timeline of GL261 intracranial tumor-bearing mice treated with or without CD73 and/or CD155 mAb. B Bioluminescence intensity and C bodyweight for intracranial GL261 tumor-bearing mice following treatment with PBS (n = 4 mice), CD155 mAb (n = 4 mice), CD73 mAb (n = 5 mice), or both CD155 and CD73 mAbs (n = 5 mice) (two-way ANOVA, Tukey’s multiple comparison test). Quantification of tumor infiltrating D CD3 + T cells E CD3 + PD-1 + T cells for intracranial GL261 tumor-bearing mice following treatment with PBS, CD155 mAb, CD73 mAb or both CD155 and CD73 mAbs (n = 4 intratumoral sections; ordinary one-way ANOVA, Tukey’s multiple comparison test) (Supplementary Fig. 10). Quantification of tumor infiltrating F NKp46+ NK cells G NKp46+GzB+ NK cells for intracranial GL261 tumor-bearing mice following treatment with PBS, CD155 mAb, CD73 mAb or both CD155 and CD73 mAbs; GzB Granzyme B (n = 4 intratumoral sections; ordinary one-way ANOVA, Tukey’s multiple comparison test) (Supplementary Fig. 10). H Percentage of various immune cells measured on tumor-infiltrating CD45+ cells in treated immunocompetent flank tumor-bearing mice measured via flow cytometry (n = 6 mice/group; ordinary one-way ANOVA, Tukey’s multiple comparison test) (Supplementary Fig. 12–13). I Phenotypic analysis of tumor-infiltrating NK and T cells isolated from treated mice measured by flow cytometry (n = 6 mice/group; two-way ANOVA, Tukey’s multiple comparison test, simple row effects) (Supplementary Figs. 12–13). Data are presented as mean values +/- SEM. Source data are provided as a Source Data file.
